Related Experiment Videos
[Radiotherapy of thymomas].
1C.H.U. Pitié-Salpêtrière, Centre des Tumeurs, Paris.
Revue Des Maladies Respiratoires
|January 1, 1988
Summary
Radiotherapy is a standardized treatment for thymomas, reducing recurrence after surgery. Current prospective trials aim to improve the 5-year survival rates, which range from 46 to 66%.
Area of Science:
- Oncology
- Radiotherapy
- Thoracic Surgery
Context:
- Thymomas are rare tumors of the thymus gland.
- Post-operative radiotherapy has been used for ten years to reduce recurrence.
- Historically, radiotherapy protocols were empirical but are now standardized.
Purpose:
- To present the standardized radiotherapy approach for thymomas.
- To review the efficacy of radiotherapy in reducing local and regional recurrence.
- To highlight the ongoing prospective trial by the Study Group of Thymic Tumors (GETT) since 1982.
Summary:
- Standardized radiotherapy involves doses of 50-60 Gy over 6-7 weeks, tailored to residual tumor volume.
- Recent retrospective trials show 5-year survival rates between 46% and 66%.
- The GETT prospective trial utilizes consistent surgical, anatomical, and treatment protocols.
Impact:
- Establishes radiotherapy as a key component in thymoma management.
- Provides benchmarks for survival rates in thymoma patients.
- Informs future research and clinical practice for thymoma treatment optimization.